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Abstract
The reported case is a 61-year-old woman, admitted for gradual onset of gait disturbances 
and dysphonia. The serum immunological panel revealed anti-Yo autoantibodies, suggestive 
of a paraneoplastic syndrome (PNS). A PET-CT revealed a suspicious left ovarian mass with 
retroperitoneal nodal involvement, and the histological assessment of surgical samples con-
firmed a FIGO IIIC high-grade serous ovarian cancer (HGSOC). Deemed inoperable at first, the 
patient was treated by carboplatin and paclitaxel chemotherapy, after which she refused sur-
gical debulking. At the end of her systemic treatment, the patient only experienced a transient 
improvement of the cerebellar ataxia. Despite the suboptimal oncological treatment, the pa-
tient still presents stable disease and is free of progression 7 years from her diagnosis. This 
case study illustrates the favorable effect of PNS occurrence on oncological outcome in a pa-
tient with advanced HGSOC. The absence of recurrence despite the presence of residual dis-
ease after the systemic treatment is unusual and could be related to the PNS.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Ovarian cancer (OC) is the fifth most common type of cancer in women. The majority 
of cases of OC are of epithelial origin (∼90%). OC is frequently asymptomatic at initial 
stages. The most common symptoms include abdominal or pelvic pain, bowel changes, 
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vaginal bleeding, abdominal distension, and fatigue, and they often appear in advanced 
stages. Rarely, ovarian carcinomas can be related to paraneoplastic neurological 
syndromes. Paraneoplastic syndrome (PNS) can be either the presenting symptom or part 
of the clinical manifestations of the underlying cancer. When PNS is the initial presentation 
of OC, it can mask and delay the diagnosis of the underlying disease [1]. PNS occurrence is 
considered as a favorable factor for tumor prognosis and cancer treatment outcome [2]. 
However, the most important prognostic factor for patients with advanced OC is residual 
disease after debulking surgery. Therefore, a maximal debulking effort is the gold standard 
for the primary treatment of OC.
Since the mid-1990s, primary debulking surgery followed by platinum- and taxane-based 
combination chemotherapy has been the standard of care for OC treatment. The aim of the 
surgical treatment is complete cytoreduction of all macroscopic visible disease, since this has 
been shown to be associated with a significantly increased overall survival (OS) and 
progression-free survival [3, 4]. The timing of cytoreductive surgery in relation to chemo-
therapy is debated, with accumulating data supporting neoadjuvant chemotherapy as a 
noninferior treatment option for patients frail or with disease too extensive to undergo 
primary debulking surgery [5].
We report the case of a patient presenting with a PNS as the first symptom of an under-
lying advanced high-grade serous ovarian cancer (HGSOC). Despite having been treated only 
by systemic chemotherapy, as she refused surgical debulking, the patient had a very good 
partial response, with persistence of only one left iliac lymphadenopathy. Her disease is still 
stable 7 years after the diagnosis.
Fig. 1. Initial PET-CT. Disease extension at diagnosis.
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Case Report
A previously healthy 61-year-old woman was referred to the hospital for investigation of 
recent onset of neurological symptoms. At admission, the patient complained of increasing 
gait disturbances and dysphonia, which had appeared gradually.
The neurological examination showed dysmetria, dysdiadochokinesia, dysarthria, and 
ataxia of stance and gait [6], and the patient was hospitalized for investigations of a rapidly 
progressive predominantly static and lower-limb cerebellar syndrome.
The initial radiological assessment by brain magnetic resonance imaging (MRI) 
showed diffuse cerebellar atrophy, predominant in the vermis. The neuropsychological 
examination revealed moderate executive dysfunction. Nerve conduction examination 
showed areflexia and the isolated absence of sensory potentials on the right superficial 
peroneal nerve.
Since the differential diagnosis of cerebellar ataxia is broad [7], the patient benefited 
from a large biological assessment, which did not reveal any abnormality of the renal or 
hepatic function or an inflammatory syndrome. Vitamin balance (vitamins B12, B9, and E) as 
well as thyroid function were also in normal range. The assay of tumor markers showed an 
increase in CA-125 (307 kU/L). Genetic examination for the most frequent spinocerebellar 
ataxias (SCA 1, 2, 3, 6, 7, and 17 genes) as well as for Friedreich’s ataxia was negative. The 
lumbar puncture showed a discrete elevation of protein concentration without pleocytosis, 
but with an intrathecal synthesis of IgG.
In order to rule out a paraneoplastic neurological syndrome, a PET-CT was carried out 
(Fig. 1–3). It showed 3 suspicious left ovarian masses and 2 pathological lymph nodes near 
the portal vein and the vena cava. The diagnosis of a cerebellar degeneration of paraneo-
Fig. 2. Initial PET-CT. Disease extension at diagnosis.
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plastic origin was thus retained. It was supported by the detection of positive anti-Yo anti-
neuronal antibodies [1].
To confirm the tumor diagnosis, a diagnostic laparoscopy with peritoneal washing and 
biopsies was performed. The histopathological analysis confirmed a FIGO IIIC HGSOC. The 
frail condition of the patient made primary debulking surgery efforts impossible. Therefore, 
the patient underwent a 6-cycle, 3-weekly carboplatin treatment dosed at 6 area under the 
curve and paclitaxel 175 mg/m2 chemotherapy treatment. Beside a satisfactory clinical, 
biological, and radiological response, with persistence of a left iliac lymph node only, the 
patient, still affected by her PNS, refused surgical debulking. Based on former treatment algo-
rithms, she received a 15-month treatment of 7.5 mg/kg bevacizumab maintenance treatment. 
Her BRCA 1/2 mutational status is unknown.
The patient went on to standard follow-up by periodic radiological assessment and 
CA-125 dosing. Seven years after her diagnosis, the radiological assessments show the persis-
tence and stability of the left iliac lymph node, without any sign of progression.
With respect to the paraneoplastic neurological syndrome evolution, despite a transient 
improvement of the cerebellar ataxia and dysarthria, the neurological impairment persists to 
this day. Neurorehabilitation, physiotherapy, and speech therapy did not help improve the 
neurological deficit of the patient. No other treatments, including corticosteroids, immuno-
globulins, or plasma apheresis, were prescribed. On brain imaging, a stable, over the years 
diffuse, central nervous system atrophy persists.
Discussion/Conclusion
In our case report, we describe the diagnosis, treatment, and outcome of a patient suffering 
from a PNS as the presenting symptom of an advanced HGSOC. Although the patient had a subop-
timal treatment without surgical debulking of the tumor, she experienced an unexpectedly long 
stable disease and is still free of progression. This patient’s history confirms reported observa-
tions associating the occurrence of PNS with a favorable oncological outcome [2].
High-grade serous is the most common subtype of epithelial ovarian adenocarcinomas. 
Their prognosis is mostly affected by stage at diagnosis and the amount of residual tumor 
Fig. 3. Initial PET-CT. Disease extension at diagnosis.
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after debulking surgery. OC staging guidelines used in our patient were updated in 2014. In 
the absence of peritoneal disease, isolated lymph node involvement beyond the pelvis was no 
longer considered as stage IIIC but as stage IIIA2 disease. This update from the FIGO 2009 to 
the FIGO 2014 staging system reflects the observed lesser impact of lymph node involvement 
in the overall prognosis of the disease, especially for stage III and IV OC without bulky lymph 
nodes. Although currently the disease stage of our patient would be less advanced, the lack of 
debulking surgery, irrespective of the systemic platinum-based chemotherapy, is a well-
established negative prognostic factor [3]. Virtually, all patients with macroscopically residual 
disease experience early recurrences and shorter OS [3, 4]. Thus, nonsurgical treatment of 
epithelial OC is not considered as a standard of care and is often regarded as palliative care. 
Indeed, Shalowitz et al. [8] reported in 2016 that about 20% of women diagnosed with OC do 
not undergo surgery. These patients are aged 75 years or older and have advanced-stage 
disease. In this cohort, patients treated with surgery had an OS of 57 months. On the contrary, 
nondebulked patients had less than 12 months of OS, while patients who received no treatment 
at all had an OS of just 1.4 months. Although there are no prospective trials comparing surgical 
to nonsurgical treatment outcomes, based on the available literature, optimal surgical cyto-
reductive effort is the milestone of the medical care of patients with newly diagnosed ovarian 
epithelial carcinoma.
Therefore, the unexpectedly long survival without signs of progression of our patient is 
rare and worth mentioning. Neither the FIGO stage update, nor the systemic treatment could 
account for this exceptional outcome. Another potential factor that could favorably influence 
the prognosis of our patient is the presence of a BRCA1/2 mutation. Although BRCA mutation-
associated OC tends to have a favorable prognosis and response to platinum treatment 
compared to wild type, counterparts at equal stage, nondebulked OCs do not show such a long 
OS with chemotherapy alone. Thus, the occurrence of the PNS seems to have positively 
affected the outcome of our patient.
Neurological manifestations seen in cancer patients are mostly the consequence of direct 
tumor invasion of the nervous system or presence of metastases. PNS are rare conditions, 
present in 1–3% of oncological patients and associated with a broad variety of tumors. They 
are a heterogeneous set of cancer-related neurological diseases and may involve any part of 
the nervous system, but they are not caused by a direct malignant tumor infiltration [9]. PNS-
related neurological symptoms can be the presenting symptoms in up to 70% of patients [1, 
9], and so they can help in the early diagnosis of the tumor, permitting the instauration of 
treatment at earlier stages [10]. As a result, cancer prognosis of patients presenting with PNS 
is usually better, although their global survival may be poor due to severe neurological 
morbidity [11].
The most common PNS associated with ovarian tumors are subacute cerebellar degen-
eration and subacute sensory neuropathy [1, 9, 10, 12]. Paraneoplastic cerebellar degener-
ation is believed to be due to an autoimmune reaction, targeted against components of the 
central nervous system, mostly Purkinje cells. It can result in rapid pan-cerebellar dysfunction, 
it can manifest several months before the presentation of neoplasms, and it is characterized 
by subacute onset of truncal and limb ataxia, dysarthria, and nystagmus. The ataxia can be 
asymmetrical at the initial presentation but usually becomes symmetrical during the disease 
evolution. Cerebrospinal fluid abnormalities, showing an inflammatory process with elevated 
protein, lymphocytic pleocytosis, and IgG synthesis are common in the early stages. MRI of 
the brain is often normal in the early stages, with later neuroimaging showing diffuse cere-
bellar atrophy. Because of the board differential diagnosis associated with PNS, an extensive 
diagnostic workup is necessary to establish the diagnosis of potentially treatable underlying 
tumors [7]. In 60% of cases, paraneoplastic cerebellar degeneration is associated with the 30 
distinct onco-neuronal antibodies [13]. An association between specific antibodies, cancer 
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type, and PNS has been reported [14]. Notably, anti-Hu are associated with small-cell lung 
cancer, anti-Tr/DNER with Hodgkin lymphoma, and anti-Yo with ovarian and breast cancer. 
These antibodies have great diagnostic as well as some prognostic value. Anti-Yo antibodies, 
also called Purkinje cell cytoplasmic antibodies type 1 (PCA-1), recognize 3 Purkinje cell 
intracellular antigens, the cerebellar degeneration-related protein 2 (CDR2), the cerebellar 
degeneration-related protein 3 (CDR3), and the cerebellar degeneration-related protein 1 
(CDR1). They result in either extensive Purkinje cell loss and less extensive granule cell loss, 
leading to cerebellar dysfunction, or intense cell differentiation, rather than cell death, leading 
to changes of the neurons’ function [1, 10].
In addition to autoantibodies, cytotoxic T cells seem to be important in the pathogenesis 
of paraneoplastic cerebellar degeneration. According to Tanaka et al. [15], human leukocyte 
antigen (HLA) class II molecules, which are present on the surface of antigen-presenting cells, 
activate the antibody production by B cells, through T cell activation. As T cells are necessary 
for the anti-Yo antibodies production, HLA class II molecules are considered to participate in 
the production of anti-Yo antibodies.
As all PNS, paraneoplastic cerebellar degeneration has no single effective treatment. 
Given the immune-mediated pathogenesis, concomitant immunotherapy, such as plasma 
exchange, corticosteroids, and immunoglobulin injections, is often prescribed but has only 
limited activity. Oncological treatments can provide various levels of relieve or stabili-
zation of the symptoms [11]. Rarely, dramatic improvements were reported. Thus, although 
PNS can have a favorable effect on the oncological prognosis of OC patients, the residual 
morbidity of these patients due to their neurological complications is impeding their 
quality of life.
This case study confirms the observation that optimal oncological management of the 
underlying malignancy provides the best chances for complete neurological recovery and 
that the presence of PNS can be associated with better oncological outcomes.
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